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ABSTRACT 
The goal of this study was to compare visual assessment of intra-tumor 18F-FDG PET 
uptake distribution with an automated quantification through textural features (TF) 
analysis and to establish their respective prognostic value in non-small cell lung cancer 
(NSCLC). 
METHODS: One hundred and two consecutive patients with NSCLC were 
retrospectively included. Only primary tumors were considered. Intra-tumor 
heterogeneity was visually scored by two nuclear medicine physicians using a 3-level 
scale (Hvisu). Metabolically active tumor volumes (MATV) were automatically delineated 
and heterogeneity was quantified through TF parameters. Mean and maximum SUV 
(SUVmean, SUVmax) were also included. Inter-observer agreement in visual assessment 
was evaluated using the Kappa test. Correlations between quantitative and visual 
assessment were evaluated using Spearman rank () coefficient. Association with 
overall survival (OS) and recurrence-free survival (RFS) was investigated using the 
Kaplan-Meier method and Cox regression models. 
RESULTS: Moderate correlations (0.4<<0.6) between TF parameters and Hvisu were 
observed. Inter-observer agreement for Hvisu was moderate (kappa=0.64), with 
discrepancies in 27% of the cases. High SUV, large metabolic volumes and high 
heterogeneity according to TF analysis was associated with poorer OS and RFS, and 
remained an independent prognostic factor of OS with respect to usual clinical 
variables. 
CONCLUSIONS: Quantification of 18F-FDG uptake heterogeneity in NSCLC through 
TF analysis is correlated with visual assessment by experts. However, TF analysis is 
also associated with an objective heterogeneity quantification, reduced inter-observer 
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variability, and independent prognostic value potentially useful for patient stratification 
and management. 
 
Keywords: 18FDG-PET/CT, heterogeneity, textural features, tumor delineation, 
prognosis, NSCLC. 
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18F-FDG Positron Emission Tomography/Computed Tomography (PET/CT) imaging is 
today a well-established tool for diagnostic oncology applications (1). Its exploitation 
for gross tumor volume delineation in radiotherapy treatment planning (2) and/or 
monitoring response to therapy (3,4) is increasing. For non-small cell lung cancer 
(NSCLC), 18F-FDG PET/CT image quantification has been shown to provide 
prognostic information. PET image-derived features, including metabolically active 
tumor volume (MATV), mean standardized uptake value (SUVmean) and total lesion 
glycolysis (TLG, defined as MATV×SUVmean) have been shown to provide an accurate 
assessment of tumor burden with potentially higher prognostic value than standard 
maximum SUV (SUVmax), for both surgical and non-surgical patients (5–9). 
Intra-tumor 18F-FDG uptake heterogeneity has been associated with treatment failure 
(10) and its quantification has recently generated interest (11–14), including in lung 
cancer (15). Several methodologies have been proposed to assess intra-tumor 
heterogeneity, including visual evaluation (16), SUV coefficient of variation (SUVCOV) 
(17), area under the curve of the cumulative histogram (CHAUC) (18), and textural 
features (TF) analysis (17,19).  
TF analysis generates a large number of features quantifying heterogeneity within a 
delineated MATV. Recent studies have identified few of these features that are robust 
to the clinical range of reconstruction algorithms and acquisitions protocols (20), the 
delineation step or partial volume effects (PVE) (21), reaching similar or better 
physiological reproducibility than SUV (22). 
However, to date there has been no study investigating whether or not the quantitative 
heterogeneity assessment of the intra-tumor activity distribution through TF represents 
an added value relative to a visual assessment by nuclear medicine physicians. This 
study was therefore designed to (i). compare a visual/qualitative tumor heterogeneity 
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assessment with a characterization through TF analysis, and (ii). assess their 
respective prognostic value in NSCLC.  
 
MATERIALS AND METHODS 
Patients & PET/CT Imaging 
One hundred and eight consecutive non-metastatic patients with newly diagnosed 
NSCLC between 2008 and 2011 were retrospectively considered. The institutional 
review board approved this retrospective study and the requirement to obtain informed 
consent was waived. Only primary tumors with MATV larger than 3 cm3 were included 
due to the inability of PET to characterize tracer distribution within smaller tumors 
because of its limited spatial resolution. As a result, 102 patients (79 men, mean age 
64) were included (table 1). There were 49 squamous cell carcinomas and 53 
adenocarcinomas. 
All patients underwent an 18F-FDG PET/CT scan before initiating treatment as part of 
the routine staging procedure within a maximum 2 weeks from diagnosis. Patients 
fasted for at least 6 hours before injection of 5 MBq/kg (425±95, range 223-690) of 18F-
FDG, administered at 60±4 minutes before data acquisition on a Philips GEMINI 
PET/CT scanner (Philips Medical Systems, Cleveland, USA). CT data were acquired 
first (120kV and 100mAs, no contrast-enhancement). 3D PET data were subsequently 
acquired with 2 min per bed position, and images were reconstructed using CT based 
attenuation correction and a 3D row-action maximum likelihood algorithm (RAMLA) 
using a previously optimized protocol (2 iterations, relaxation parameter equal to 0.05, 
5 mm full-width-at-half-maximum 3-D Gaussian post-filtering, 4×4×4 mm3 voxels grid 
sampling) (23). SUVs were normalized using the patient body weight. 
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Treatment & Follow-up 
Treatment consisted of surgery for 48 patients [surgery only (n=18), adjuvant 
chemotherapy (n=20), radiochemotherapy (n=9), or radiotherapy (n=1) followed by 
surgery], whereas 54 patients did not undergo surgery [chemotherapy (n=12) or 
concomitant chemo-radiotherapy (n=42)] (Supplemental Fig. 1). Chemotherapy 
consisted of 2 to 6 courses (median=4) of cisplatine/carboplatine in association with 
taxol, navelbine, gemcitabine or pemetrexed. The mean total radiotherapy dose was 
59.4Gy. 
Patients were followed with clinical examination and CT every 3-4 months. Overall 
survival (OS) and recurrence-free survival (RFS) were defined as the time between 
diagnosis and death (or last follow-up), and between the end of treatment and 
recurrence respectively. 
 
Image Analysis 
Only the primary tumors were analyzed. Intra-tumor heterogeneity was first scored by 
two observers (denoted Hvisu from here onwards), and quantified through TF analysis 
after MATV automatic delineation. 
Two experienced nuclear medicine physicians were asked to review all PET images, 
blinded to the survival information and heterogeneity quantification. They assigned to 
each primary tumor a score on a 3-point scale: 1 for homogeneous distribution, 2 for 
moderately heterogeneous and 3 for highly heterogeneous. An alternative scale was 
considered by adding two sub-levels, A for “diffuse” or B for “focalized” heterogeneity, 
in scores 2 and 3, hence resulting in a 5-score scale: 1, 2A, 2B, 3A, 3B. For instance, 
centrally necrotic tumours were scored as 3B (Fig. 1C). 
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In order to carry out the quantitative heterogeneity analysis, MATV were firstly 
delineated using the Fuzzy Locally Adaptive Bayesian (FLAB) algorithm (24,25). FLAB 
computes a probability of belonging to a given “class” (e.g. tumor with high or moderate 
uptake, and background) for each voxel within a 3D ROI containing the tumor and its 
surrounding physiological background. This probability is iteratively estimated by 
taking into account the voxel’s intensity with respect to the statistical distributions 
(characterized by their mean and variance) within the ROI, and its spatial correlation 
with neighbouring voxels. This approach has been previously validated for accuracy, 
robustness and reproducibility using simulated and clinical datasets, including 
homogeneous and heterogeneous MATVs (26–28). FLAB was exploited in this work 
using 2 or 3 classes in order to adequately cover the entire MATV, including low uptake 
regions.  
Intra-tumor uptake heterogeneity was quantified considering few textural features that 
have been previously shown as robust considering variability in image reconstruction 
and acquisition protocols (20), and physiological reproducibility based on test-retest 
acquisitions (22). Considered local heterogeneity parameters quantifying intensity 
variations between each voxel and its immediate neighbours only, averaged over the 
entire volume were entropy (E), homogeneity (H) and dissimilarity (D). Regional 
heterogeneity parameters calculated through analysis at the level of groups of voxels 
and areas of various sizes and intensities were high intensity emphasis (HIE), size-
zone variability (SZV) and zone percentage (ZP). A 64 grey level resampling was used, 
and local features were computed over 13 directions (19,22). 
Other global parameters such as skewness or kurtosis were excluded considering their 
previously demonstrated poor robustness (20) and/or physiological reproducibility (22). 
CHAUC and high intensity emphasis (HIE) were computed after applying edge-
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preserving filtering (29) and PVE correction (30), as it has been previously shown that 
such pre-processing is necessary for these parameters (18,21). 
Finally, SUVmax, SUVmean, MATV and TLG were also included for comparison purposes 
as they have been previously shown to provide prognostic value in NSCLC (5–9). 
 
Statistical Analysis 
Statistical analyses were performed using MedcalcTM (MedCalc Software, Belgium). 
Inter-observer’s agreement regarding Hvisu was estimated using the weighted Kappa 
test with linear weights. Correlation between Hvisu and quantitative features was 
assessed using Spearman's  rank correlation. Variables with non-normal distributions 
(e.g. MATV) were log-transformed. 
The prognostic value of each feature for overall survival (OS) and recurrence-free 
survival (RFS) was assessed through univariate analysis using Kaplan-Meier curves 
and the log-rank test, with optimal cut-off values determined through receiver operating 
characteristic (ROC) analysis. Statistically significant differences were considered for 
p<0.05 after Bonferroni correction for multiple testing. 
Multivariate analysis was performed with Cox regression by including clinical variables 
along with image-derived features as continuous variables. Since there were 62 
deaths, no more than 6 uncorrelated variables were included in separate models for 
OS.  
 
RESULTS 
Inter-observer’s Agreement 
Figure 1 illustrates three tumors with Hvisu values of 1, 2 and 3. About half of the tumors 
were scored as highly heterogeneous. Using the 3-point scale, inter-observer’s 
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agreement reached a moderately satisfactory level with a weighted kappa value of 0.64 
(95% CI 0.52 to 0.75). The two observers were in agreement on the visual score for 
74/102 tumors (73%). All discrepancies occurred between consecutive scores (1 and 
2 or 2 and 3, never 1 and 3) (Supplemental Table 1). Using the five-level scale, inter-
observer’s agreement decreased to 0.58 (95% CI 0.47 to 0.70), the two observers 
agreeing on 62/102 (61%) (Supplemental Table 2). For the subsequent analysis, only 
the 3-point scale was considered, and only one value of Hvisu obtained through 
consensus was used. 
 
Correlation Between Visual Scoring and Quantitative Heterogeneity 
Significant correlations were observed between Hvisu and quantitative features 
(Supplemental Table 3). Highest correlations were observed for local and regional TF 
with from 0.59 to 0.61 except ZP and HIE (0.44, p<0.0001 and 0.20, p=0.04 
respectively). CHAUC was not correlated with Hvisu (0.07, p=0.5), whereas SUVCOV 
showed similar correlation as HIE (0.22, p=0.027) (Supplemental Fig 2). 
SUVmax and SUVmean were not correlated with MATV (r<0.2). On the other hand, TF 
showed variable levels of correlation with MATV, with r=0.6, -0.7 and 0.7 for entropy, 
dissimilarity and homogeneity respectively, and r=-0.5, -0.6 and -0.3 for SZV, ZP and 
HIE respectively. These correlations show that although heterogeneity is correlated 
with volume, such heterogeneity measurements could provide complementary 
information. 
 
Survival Analysis 
Median follow-up was 36.6±11.8 months. After surgery, 32 patients had evidence of 
recurrence. At the time of last follow-up, 39 patients were alive. Median OS and RFS 
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were 18.4 (range 1-58, 95% CI 14.5-23.1), and 11.4 (range 1-58, 95% CI 6.8-18.4) 
months respectively.  
In the univariate analysis (table 2), surgery (p=0.006), gender (p=0.02), age (p=0.03) 
and stage (p=0.001) were significantly associated with OS, as well as standard SUV 
or volume parameters (p from 0.009 for SUVmax to <0.0001 for MATV). For instance, 
patients with MATV>35 cm3 had a median survival of 10 months vs. 49 months for 
those with MATV≤35 cm3. Patients who underwent surgery survived almost twice as 
long (median survival of 28 months) compared to those who did not (median survival 
of 15 months). 
Higher visual heterogeneity (Hvisu=3) was associated with poorer OS, although the 
trend was not statistically significant. Patients with Hvisu=3 had a median survival of 17 
months, whereas those with Hvisu<3 had a median survival of 20 months. Higher 
heterogeneity assessed by TF was associated with poorer OS (p≤0.007 for local TF 
and <0.0001 for regional TF, except HIE). For example, entropy>0.75 was associated 
with a median survival of 11 months vs. 49 months for those with entropy≤0.75. 
SUVCOV and CHUAUC were not associated with OS (p=0.4 and 0.9 respectively). Figure 
3 provides examples of Kaplan-Meier curves for the different parameters considered. 
In the multivariate Cox models that included surgery, gender, stage, SUVmax (or 
SUVmean) and either MATV, TLG or one heterogeneity parameter (since these latter 
are correlated with each other), stage remained an independent prognostic factor but 
not surgery, gender and SUVmax (or SUVmean). MATV, as well as all heterogeneity 
quantification parameters obtained through TF, except HIE, remained independent 
prognostic factors with respect to stage (although not independent on each other).  
The addition of risk factors allowed a better differentiation of patients’ outcome. 
Patients with large MATV combined with high local and regional tracer heterogeneity 
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had a median survival of 9 months and a 3-year survival rate of 0%, whereas the other 
group had a median survival of 49 months and a 3-year survival rate of 50% (Fig. 5). 
The complementary value of TF heterogeneity to MATV can be shown by comparing 
the finer stratification of patients into 4 groups with statistically different outcomes (Fig. 
6). MATV combined with entropy (Fig. 6B) led to different survival curves compared to 
the use of MATV alone (Fig. 6A). MATV>50 cm3 were associated with longer survival 
than MATVs between 35 and 50 cm3. However, among volumes above 35 cm3, those 
with entropy>0.95 had significantly shorter survival (Fig. 6B). 
Concerning recurrence free survival none of the patients treated with 
chemoradiotherapy achieved complete response, therefore only patients who 
underwent surgery were included (table 3). None of the clinical variables were 
associated with RFS. MATV (p=0.001) and TLG (p=0.03) were significant prognostic 
factors of RFS, in contrast to SUV measurements. Hvisu=3 was associated with a 
median RFS of 7 months whereas median RFS was 25 months for those with Hvis<3, 
although this trend was not statistically significant (p=0.3). Higher heterogeneity as 
quantified through TF analysis was significantly associated with poorer RFS (p≤0.004), 
except when using HIE. For example, patients with a dissimilarity>0.57 had a median 
RFS of 6 months vs. 25 months for those with dissimilarity≤0.57. No multivariate 
analysis was performed for RFS due to the lack of uncorrelated variables statistically 
significant in the univariate analysis. Figure 4 provides examples of corresponding 
Kaplan-Meier curves. 
 
DISCUSSION 
There is currently an increasing interest in the use of PET image derived features 
allowing the quantification of intra-tumor heterogeneity (11,12). Visual assessment 
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may be considered as a simple and valuable way of scoring intra-tumor tracer 
distribution. In the present study, visual/qualitative and quantitative assessment of 
heterogeneity were simultaneously considered in the same NSCLC patient cohort and 
compared in terms of prognostic value. 
Firstly, our results suggest that quantitative parameters obtained through TF analysis 
are correlated with the visual assessment by nuclear medicine physicians. Our study 
also demonstrated an added value for TF analysis over visual assessment. The first 
advantage is that, as MATV and heterogeneity determination is fully automatic, the 
only inter- or intra-observer variability that might occur lies in the tumor location 
identification. Automated characterization is therefore likely to reduce inter-observer 
variability associated with visual assessment, which as shown in this study was an 
issue for 27% of the cases. This was even worse when considering a larger scale for 
visual scoring, with a substantial decrease of inter-observer agreement from 0.64 to 
0.58 (from 73% to 61% of the 102 tumors). As a result this finer scale was not further 
exploited, clearly demonstrating the difficulty in reaching a fine visual characterization 
of intra-tumor tracer distribution.  
A recent study comparing visual heterogeneity scoring, SUVCOV and CHAUC found high 
correlations (0.72&0.87 for SUVCOV&CHAUC respectively) (31). In our study, lower 
correlations were found between Hvisu and TF, whereas SUVCOV and CHAUC were not 
correlated with Hvisu. Several factors may explain this difference. This previous study 
included only 9 gastrointestinal stromal tumors (GIST) and 12 malignant lymphomas 
(ML), manually delineated within a single 2D slice. A four-value scale was used for 
visual scoring and inter-observer variability was not reported. The authors did not take 
into account the difference in volumes between GIST and ML. These volumes were 
also much larger (119±102 cm3) than in our study (48±58 cm3), suggesting that CHAUC 
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and SUVCOV might be appropriate to characterize high heterogeneity levels as found 
in very large GIST and ML lesions, but may not be sufficient to quantify finer 
heterogeneity differences found in smaller NSCLC tumors. This is also supported by 
the distributions of CHAUC values with a small range (SD=0.05) in our study (0.32±0.05) 
compared to those found in Watabe et al (0.41±0.14 for GIST and 0.64±0.08 for ML) 
(31). 
The second advantage of TF analysis is that it leads to additional prognostic value that 
may be useful for patient management. A stronger differentiation between groups of 
patients with different outcome was highlighted by combining parameters, albeit being 
correlated with each other. As an example, patients with MATV>35 cm3 combined with 
entropy>0.74 and zone percentage≤0.32 had a median survival of 9 months and a 3-
year survival of 0%, whereas the others had a median survival of 60 months and a 3-
year survival of 50% (Fig. 5). As shown in figure 6, despite the correlation between TF 
parameters and MATV, patient outcome could not be fully described using the MATV 
alone (Fig. 6A). This is illustrated in figure 6B, showing that smaller but more 
heterogeneous lesions were associated with poorer OS than larger and more 
homogeneous ones. 
A recent study suggested that entropy is unable to predict tracer uptake heterogeneity 
for tumors with MATV<45 cm3 (32). In our cohort, volumes were 48±58 cm3 (range 3-
415, median=34). Our results only partly confirm this, since entropy provided additional 
information with respect to MATV in larger volumes (Fig. 6). MATV between 30 and 45 
cm3 exhibited an entropy between 0.55 and 0.81 (Supplemental Fig. 3A), with a weak 
correlation of r=0.57. For tumours with volumes <30 cm3 this correlation was equal to 
0.95, suggesting that for MATV<30 cm3 the information provided by entropy was 
indeed similar to that of volume. Finally, the proposed threshold value of 45 cm3 may 
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not be applicable for other heterogeneity measurements, since in our study different 
values of homogeneity or zone percentage were observed for similar volumes down to 
the lower limit of 3 cm3 (Supplemental Fig. 3B, 3C).   
Regarding the prognostic value of PET parameters in NSCLC, including SUV, MATV 
and derived TLG (5–9) and TF (15), our findings are in line with previous results. The 
only study that investigated the prognostic value of 18F-FDG PET heterogeneity in 
NSCLC was conducted on 53 patients with stage 3 and above, exclusively treated with 
combined chemoradiotherapy (non-surgical patients) (15). Their results regarding 
MATV and TLG, showing no significant association with outcome might be confounded 
by the fact that all their patients were stage 3 and 4 combined with the use of a fixed-
thresholding delineation approach. However, considering tracer distribution they found 
that heterogeneity quantified through busyness, coarseness, contrast and complexity 
was significantly associated with RFS and OS. None of these parameters were 
included in our study because we have previously demonstrated their lower 
reproducibility (22). However, although our parameters were different and extracted 
from MATVs delineated using a more robust segmentation method, we also found that 
intra-tumor 18F-FDG heterogeneity was significantly associated with outcome, for non-
surgical patients but also for surgical ones, which have not been evaluated in previous 
studies. In the present study, the heterogeneity parameters obtained through TF 
analysis remained independent prognostic factors of OS with respect to standard 
clinical variables such as gender, age, stage and surgery, in contrast to visual 
heterogeneity assessment.  
Our study is limited by its retrospective nature. It included a mixture of different 
treatments (with or without surgery, radiotherapy, chemotherapy), leading to a 
heterogeneous cohort. However, the relatively large number of patients and events 
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allowed taking into account surgery in the survival analysis. The large number of 
squamous cell carcinomas in our cohort was due to the exclusion of metastatic disease 
(mostly adenocarcinomas), since related patient management and prognosis greatly 
differ. We considered more interesting to assess new parameters to refine patient 
stratification beyond the well-established TNM classification.  
A last limitation of our study is that we focused on the primary tumor. Including lymph 
nodes in the analysis could be of importance due to their impact on prognosis (33), but 
was outside the scope of the present study focusing on tracer distribution 
heterogeneity, which is meaningless to assess on small structures such as lymph 
nodes, considering the limited spatial resolution in PET imaging. The main objective of 
this study was to determine whether or not automated quantification through TF 
analysis could relate to visual assessment of PET images, and primary tumor analysis 
was sufficient within this context. 
 
CONCLUSIONS 
Automated quantification of intra-tumor 18F-FDG uptake heterogeneity in NSCLC 
through textural feature analysis provides parameters that are correlated with visual 
analysis by experts. Nevertheless, our results also highlight several advantages of 
using automated quantification, including objective heterogeneity evaluation with 
reduced inter-observer variability, and more clinically pertinent stratification through 
independent prognostic factors in NSCLC. 
  
 16 
References 
1.  Krause BJ, Schwarzenbock S, Souvatzoglou M. FDG PET and PET/CT. 
Recent Results Cancer Res. 2013;187:351–69. 
2.  Jarritt PH, Carson KJ, Hounsell AR, Visvikis D. The role of PET/CT scanning 
in radiotherapy planning. Br J Radiol. 2006;79 Spec No 1:S27–35. 
3.  Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: 
Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 
2009;50 Suppl 1:122S–50S. 
4.  Herrmann K, Benz MR, Krause BJ, Pomykala KL, Buck AK, Czernin J. (18)F-
FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and 
where we can go. Q J Nucl Med Mol Imaging. 2011;55(6):620–32. 
5.  Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body 
total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. 
Radiology. 2012;264(2):559–66. 
6.  Kahraman D, Holstein A, Scheffler M, et al. Tumor lesion glycolysis and tumor 
lesion proliferation for response prediction and prognostic differentiation in patients 
with advanced non-small cell lung cancer treated with erlotinib. Clin Nucl Med. 
2012;37(11):1058–1064. 
7.  Kim K, Kim S-J, Kim I-J, Kim YS, Pak K, Kim H. Prognostic value of volumetric 
parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell 
lung cancer. Nucl Med Commun. 2012;33(6):613–620. 
8.  Liao S, Penney BC, Wroblewski K, et al. Prognostic value of metabolic tumor 
burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur 
J Nucl Med Mol Imaging. 2012;39(1):27–38. 
9.  Hyun SH, Ahn HK, Kim H, et al. Volume-based assessment by (18)F-FDG 
PET/CT predicts survival in patients with stage III non-small-cell lung cancer. Eur J 
Nucl Med Mol Imaging. 2014;41(1):50–58. 
10.  Basu S, Kwee TC, Gatenby R, Saboury B, Torigian DA, Alavi A. Evolving role 
of molecular imaging with PET in detecting and characterizing heterogeneity of 
cancer tissue at the primary and metastatic sites, a plausible explanation for failed 
attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging. 2011;38(6):987–
91. 
11.  Visvikis D, Hatt M, Tixier F, Cheze Le Rest C. The age of reason for FDG PET 
image-derived indices. Eur J Nucl Med Mol Imaging. 2012;39(11):1670–2. 
12.  Lambin P, Rios-Velazquez E, Leijenaar R, et al. Radiomics: extracting more 
information from medical images using advanced feature analysis. Eur J Cancer. 
2012;48(4):441–6. 
13.  Chicklore S, Goh V, Siddique M, Roy A, Marsden PK, Cook GJ. Quantifying 
tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl 
Med Mol Imaging. 2013;40(1):133–40. 
14.  Davnall F, Yip CS, Ljungqvist G, et al. Assessment of tumor heterogeneity: an 
emerging imaging tool for clinical practice? Insights Imaging. 2012;3(6):573–89. 
15.  Cook GJ, Yip C, Siddique M, et al. Are pretreatment 18F-FDG PET tumor 
textural features in non-small cell lung cancer associated with response and survival 
after chemoradiotherapy? J Nucl Med. 2013;54(1):19–26. 
16.  Miller TR, Pinkus E, Dehdashti F, Grigsby PW. Improved prognostic value of 
18F-FDG PET using a simple visual analysis of tumor characteristics in patients with 
cervical cancer. J Nucl Med. 2003;44(2):192–7. 
17.  El Naqa I, Grigsby P, Apte A, et al. Exploring feature-based approaches in 
PET images for predicting cancer treatment outcomes. Pattern Recognit. 
 17 
2009;42(6):1162–1171. 
18.  Van Velden FH, Cheebsumon P, Yaqub M, et al. Evaluation of a cumulative 
SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG 
uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 
2011;38(9):1636–47. 
19.  Tixier F, Le Rest CC, Hatt M, et al. Intratumor heterogeneity characterized by 
textural features on baseline 18F-FDG PET images predicts response to concomitant 
radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52(3):369–78. 
20.  Galavis PE, Hollensen C, Jallow N, Paliwal B, Jeraj R. Variability of textural 
features in FDG PET images due to different acquisition modes and reconstruction 
parameters. Acta Oncol. 2010;49(7):1012–6. 
21.  Hatt M, Tixier F, Cheze Le Rest C, Pradier O, Visvikis D. Robustness of 
intratumour 18F-FDG PET uptake heterogeneity quantification for therapy response 
prediction in oesophageal carcinoma. Eur J Nucl Med Mol Imaging. 
2013;40(11):1662–1671. 
22.  Tixier F, Hatt M, Le Rest CC, Le Pogam A, Corcos L, Visvikis D. 
Reproducibility of tumor uptake heterogeneity characterization through textural 
feature analysis in 18F-FDG PET. J Nucl Med. 2012;53(5):693–700. 
23.  Visvikis D, Turzo A, Gouret A, et al. Characterisation of SUV accuracy in FDG 
PET using 3-D RAMLA and the Philips Allegro PET scanner. J Nucl Med. 
2004;45(5):103. 
24.  Hatt M, Cheze le Rest C, Turzo A, Roux C, Visvikis D. A fuzzy locally adaptive 
Bayesian segmentation approach for volume determination in PET. IEEE Trans Med 
Imaging. 2009;28(6):881–93. 
25.  Hatt M, Cheze le Rest C, Descourt P, et al. Accurate automatic delineation of 
heterogeneous functional volumes in positron emission tomography for oncology 
applications. Int J Radiat Oncol Biol Phys. 2010;77(1):301–8. 
26.  Hatt M, Cheze Le Rest C, Albarghach N, Pradier O, Visvikis D. PET functional 
volume delineation: a robustness and repeatability study. Eur J Nucl Med Mol 
Imaging. 2011;38(4):663–72. 
27.  Hatt M, Cheze-le Rest C, van Baardwijk A, Lambin P, Pradier O, Visvikis D. 
Impact of tumor size and tracer uptake heterogeneity in (18)F-FDG PET and CT non-
small cell lung cancer tumor delineation. J Nucl Med. 2011;52(11):1690–7. 
28.  Hatt M, Cheze-Le Rest C, Aboagye EO, et al. Reproducibility of 18F-FDG and 
3’-deoxy-3’-18F-fluorothymidine PET tumor volume measurements. J Nucl Med. 
2010;51(9):1368–76. 
29.  Le Pogam A, Hanzouli H, Hatt M, Cheze Le Rest C, Visvikis D. Denoising of 
PET images by combining wavelets and curvelets for improved preservation of 
resolution and quantitation. Med Image Anal. 2013;17(8):877–891. 
30.  Boussion N, Cheze Le Rest C, Hatt M, Visvikis D. Incorporation of wavelet-
based denoising in iterative deconvolution for partial volume correction in whole-body 
PET imaging. Eur J Nucl Med Mol Imaging. 2009;36(7):1064–75. 
31.  Watabe T, Tatsumi M, Watabe H, et al. Intratumoral heterogeneity of F-18 
FDG uptake differentiates between gastrointestinal stromal tumors and abdominal 
malignant lymphomas on PET/CT. Ann Nucl Med. 2012;26(3):222–227. 
32.  Brooks FJ, Grigsby PW. The effect of small tumor volumes on studies of 
intratumoral heterogeneity of tracer uptake. J Nucl Med Off Publ Soc Nucl Med. 
2014;55(1):37–42. 
33.  Cuaron J, Dunphy M, Rimner A. Role of FDG-PET scans in staging, response 
assessment, and follow-up care for non-small cell lung cancer. Front Oncol. 
 18 
2012;2:208. 
 
  
 19 
 
 
 Figure 1  
  
 20 
 
Figure 2 
  
 21 
 
 
 
 
Figure 3 
  
 22 
 
Figure 4 
  
 23 
 
Figure 5 
 
  
 24 
 
 
Figure 6 
 
 
 25 
Figure captions 
 
Figure 1. Illustration primary lung tumors with Hvisu values of 1, 2 and 3 (A, B and C 
respectively). Green contours are the FLAB delineations and examples of features are 
provided (values normalized between 0 and 1).  
 
Figure 2. Illustration of the distributions of A) homogeneity and B) zone percentage 
according to the three levels of Hvisu. 
 
Figure 3. Examples of survival curves for OS (n=102) according to A) Stage, B) 
SUVmax, C) Hvisu, D) zone percentage. 
 
Figure 4. Examples of survival curves for RFS (n=48) according to A) Hvisu, B) 
dissimilarity. 
 
Figure 5. Survival curves for OS (n=102) with the stratification obtained according to 
the combination of MATV, entropy and zone percentage. 
 
Figure 6. Differentiation of four different overall survival groups using A) MATV alone 
or B) MATV and sub-stratification with entropy. 
  
 26 
Table 1. Patient Characteristics 
 
Characteristic No. of patients in % (n=102) 
Sex   
  Male 79 (78) 
  Female 23 (22) 
Age (y)   
  Range 48-84 
  Median ± SD 64 ± 8.9 
Smoker   
  No 16 (16) 
  Yes 86 (84) 
Treatment   
  Surgery only 18 (18) 
  Chemotherapy only 12 (12) 
  Radiotherapy only 0 (0) 
 Surgery + chemotherapy 20 (19) 
 Surgery + radiotherapy 1 (1) 
 Chemotherapy + radiotherapy 42 (41) 
 Chemotherapy + radiotherapy + surgery 9 (9) 
TNM stage   
  T1 13 (13) 
  T2 55 (53) 
  T3 21 (21) 
  T4 13 (13) 
  N0 32 (31) 
  N1 23 (23) 
  N2 29 (28) 
  N3 18 (18) 
  M0 102 (100) 
  M1 0 (0) 
Clinical stage   
 I 18 (18) 
 II 30 (29) 
 III 54 (53) 
 IV 0 (0) 
Histology   
 Adenocarcinoma 53 (52) 
 Squamous cell carcinoma 49 (48) 
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Table 2: OS analysis (n=102) 
 
Parameters 
p-value 
Univariate Multivariate 
Clinical 
Surgery 0.006 - 
Age 0.03 - 
Sex 0.02 - 
Smoker 0.9 - 
Histology 0.3 - 
Stage 0.001 <0.03 
SUV and 
volumetric 
SUVmax 0.009 - 
SUVmean 0.008 - 
MATV <0.0001 0.0001 
TLG 0.001 0.006 
Global 
heterogeneity 
SUVCOV 0.4 - 
CHAUC 0.9 - 
Visual 
heterogeneity 
Hvisu≥2 1 - 
Hvisu=3 1 - 
Local 
heterogeneity 
(TF) 
E <0.0001 0.0001 
H 0.008 0.03 
D 0.007 0.01 
Regional 
heterogeneity 
(TF) 
HIE 0.9 - 
SZV <0.0001 0.0002 
ZP <0.0001 0.0001 
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Table 3: RFS analysis (n=48) 
 
Parameters Univariate 
p-value 
Clinical 
Age 0.9 
Sex 0.2 
Smoker 0.1 
Histology 0.7 
Stage 0.1 
SUV and volumetric 
SUVmax 1 
SUVmean 0.6 
MATV 0.001 
TLG 0.03 
Visual heterogeneity 
Hvisu≥2 1 
Hvisu=3 0.3 
Global heterogeneity 
SUVcov 1 
CHAUC 0.8 
Local heterogeneity 
(TF) 
E 0.004 
H 0.005 
D 0.001 
Regional 
heterogeneity (TF) 
HIE 0.7 
SZV 0.004 
ZP 0.004 
 
